J&J, Bayer Hit With $28M Verdict In 1st Xarelto Loss

Law360, Philadelphia (December 5, 2017, 12:31 PM EST) -- A Philadelphia jury delivered a first-of-its-kind verdict on Tuesday as it awarded almost $28 million in damages against a pair of Johnson & Johnson and Bayer AG units after finding the companies had provided inadequate warnings about the risks of bleeding associated with the blood thinner Xarelto.

Tuesday's trial loss for units of Bayer and Johnson & Johnson comes after they won three previous bellwether cases over Xarelto's risks. (Getty) The verdict, which credited claims from an Indiana woman who said she suffered a serious gastrointestinal bleed while using the medication, comes after juries in federal multidistrict litigation sided with the drugmakers...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS